Holen Sie sich die Stockscreener-App
2.09
3.24%
-0.07
Handel nachbörslich:
2.13
0.04
+1.91%
Schlusskurs vom Vortag:
$2.16
Offen:
$2.2
24-Stunden-Volumen:
4,737
Relative Volume:
0.13
Marktkapitalisierung:
$81.82M
Einnahmen:
$24.38M
Nettoeinkommen (Verlust:
$-53.95M
KGV:
-0.8462
EPS:
-2.47
Netto-Cashflow:
$-23.31M
1W Leistung:
+12.97%
1M Leistung:
+7.73%
6M Leistung:
-39.42%
1J Leistung:
-52.28%
1-Tages-Spanne:
$2.09
$2.20
1-Wochen-Bereich:
$1.79
$2.23
52-Wochen-Spanne:
$1.61
$5.12
Elutia Inc Stock (ELUT) Company Profile
Firmenname
Elutia Inc
Sektor
Branche
Telefon
240-247-1143
Adresse
12510 PROSPERITY DRIVE, SILVER SPRING
Vergleichen Sie ELUT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
2.09 | 81.82M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
134.44 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.32 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.28 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.39 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.79 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-02 | Eingeleitet | Cowen | Outperform |
| 2020-11-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-11-02 | Eingeleitet | Truist | Buy |
Elutia Inc Aktie (ELUT) Neueste Nachrichten
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price - simplywall.st
Elutia Inc. (NASDAQ:ELUT) Shares Purchased by Millennium Management LLC - Defense World
Citadel Advisors LLC Acquires Shares of 22,431 Elutia Inc. (NASDAQ:ELUT) - Defense World
Brokers Issue Forecasts for Elutia FY2026 Earnings - Defense World
Elutia (NASDAQ:ELUT) Shares Down 1% – Time to Sell? - Defense World
Aziyo Biologics Holds Annual Stockholders Meeting - TipRanks
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET By Investing.com - Investing.com South Africa
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET - Investing.com
Elutia v. Medtronic: Delaware court rules on indemnity and insurance obligations in FiberCel lawsuit - Insurance Business America
ELUT stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
ELUT stock touches 52-week low at $1.61 amid market challenges - Investing.com India
Elutia Inc. Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method - marketscreener.com
Elutia announces publication of article on measuring antibiotic release - TipRanks
Elutia (ELUT) Innovates with New Antibiotic Release Method | ELUT Stock News - GuruFocus
Revolutionary Drug Testing Method Cuts Medical Device Development Time from 14 Days to Just 30 Hours - Stock Titan
FY2025 EPS Estimates for Elutia Lifted by Cantor Fitzgerald - Defense World
Lake Street Capital Has Lowered Expectations for Elutia (NASDAQ:ELUT) Stock Price - Defense World
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock N - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Sto - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Stock News - GuruFocus
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock News - GuruFocus
Elutia Q1 2025 slides: EluPro sales surge 84% amid overall revenue decline - Investing.com Nigeria
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition - Yahoo Finance
Elutia Inc. Reports Strong Growth in EluPro Sales - TipRanks
Earnings call transcript: Elutia Q1 2025 beats EPS forecast, stock rises - Investing.com
SEC Form 424B5 filed by Elutia Inc. - Quantisnow
Elutia Inc Reports Q1 2025 Earnings: EPS of -$0.21 Meets Estimates, Revenue of $3.1 Million Misses Estimates - GuruFocus
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - The Manila Times
Elutia Inc (ELUT) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Renaissance Technologies LLC Sells 11,700 Shares of Elutia Inc. (NASDAQ:ELUT) - Defense World
Elutia Inc. Ends Distribution Agreement with LeMaitre - TipRanks
Elutia Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Aziyo Biologics (ELUT) Receives a New Rating from Lake Street - The Globe and Mail
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | ELUT Stock News - GuruFocus
Elutia (ELUT) Resumes Direct Control Over Cardiovascular Portfol - GuruFocus
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - The Manila Times
Elutia Ends LeMaitre Partnership: Strategic Shift Promises 80% Margins in $2.9M Cardiovascular Line - Stock Titan
Elutia Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - The Manila Times
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Ou - GuruFocus
Elutia to Participate in Chardan's Trending Issues in Drug Devel - GuruFocus
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Finanzdaten der Elutia Inc-Aktie (ELUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Elutia Inc-Aktie (ELUT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HighCape Capital, L.P. | Director |
Feb 03 '25 |
Buy |
2.50 |
420,000 |
1,050,000 |
9,520,232 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Jul 31 '24 |
Option Exercise |
1.43 |
105,080 |
150,002 |
257,823 |
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):